News Adaptimmune revives ovarian cancer trial T-cell trial will include controversial chemo agent fludarabine.
News Adaptimmune progresses T-cell therapy trial Biotech says "robust" clinical response in early stage trial.
Views & Analysis Promise for combination approach to cancer As immuno-oncology increasingly involves more than one agent for best efficacy, market positioning must take a pan-tumour approach.
Oncology LSX2026: Addressing adult eye cancer, with Roi Raz Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
